Health and Human Services Secretary Robert F. Kennedy Jr. has overhauled a key FDA advisory committee, which now convenes this week to decide whether to expand the list of peptides that compounding pharmacies can produce. The move has stirred deep divisions among industry observers over how these substances should be regulated.
The Pharmacy Compounding Advisory Committee (PCAC) is set to meet Thursday and Friday to weigh adding several peptides—including BPC-157, KPV, TB-500, MOTs-C, emideltide, semax, and epitalon—to the 503A bulk compounding list. These peptides, in both freebase and acetate forms, are touted for potential benefits ranging from treating ulcerative colitis and wound healing to addressing obesity, osteoporosis, opioid withdrawal, migraines, and insomnia.
Kennedy has publicly declared himself a “big fan” of peptides, a stance that aligns with the Make America Healthy Again (MAHA) movement, which has embraced BPC-157 for its purported healing properties. However, critics point to a glaring lack of human safety data—most evidence comes from rodent studies—raising serious questions about the rush to expand access.
503A compounding pharmacies are designed to create personalized medications for individual patients, such as removing allergens or altering dosage forms. They are widely seen as the safest channel for peptide access, especially as an unregulated gray market has exploded online, with sellers hawking “research-grade” peptides for self-injection without medical supervision.
“The substances themselves have really not undergone testing of any significant kind, despite being very active pharmaceutical ingredients that are often injected,” said Shabbir Safdar, executive director of the Partnership for Safe Medicines, in an interview. He argued that the absence of robust efficacy data is stark, a view echoed by FDA scientists. In briefing materials, FDA staff concluded there is “a lack of evidence to make a conclusion on the effectiveness of BPC-157 for treating ulcerative colitis” and that current information “weighs against” adding it to the list—a finding repeated for all peptides under consideration.
Proponents of broader peptide access worry the committee’s review applies a pharmaceutical standard that doesn’t fit these substances. “The perceptual overlay being used to validate safety is the same as for pharmaceutical products, and I think it’s a mismatch,” said Jeff Cohen, co-founder of the American Peptide Association. He noted that while some drugs are peptides, not all peptides are drugs; many are naturally occurring protein fragments not owned by any company. “Those are not products for which there’s intellectual property protection that could justify tens of millions of dollars of double-blind studies,” Cohen added.
The regulatory gray zone is further complicated by the fact that several peptides on the agenda are synthetic and patented. It remains unclear whether compounding pharmacies selling versions of these patented peptides would face pressure to prove efficacy, or if patent holders would be compelled to validate the claims driving their marketing.
Safdar dismissed the notion that peptides should escape rigorous testing. “It’s hard to take it seriously when on one hand you say you’re the safer supply chain and on the other hand you say, ‘But we can’t test because it would be too expensive,’” he said. “At the 50,000-foot level, what they’re suggesting is that we run a giant uncontrolled human trial with no placebo arm.”
Because compounded medications are not FDA-approved, the agency’s oversight is limited—but a committee sign-off could be misinterpreted by consumers as official approval. This dynamic echoes broader debates about healthcare oversight, including ongoing efforts to crack down on fraud in programs like Medicaid home healthcare, where oversight has been criticized as lax. Meanwhile, the Trump administration has signaled a tougher stance on healthcare fraud, with RFK Jr. and Dr. Oz expected to detail new enforcement measures.
The PCAC’s decision this week will test whether the push for peptide access can reconcile safety and efficacy demands with the realities of a market driven by patient demand and limited patent protection.
